Suppr超能文献

变应性鼻炎潜在临床诊断和预后标志物的筛查与分析

Screening and analysis for potential clinical diagnostic and prognostic markers in allergic rhinitis.

作者信息

Liu Yejun, Kong Yonggang, Zhou Xuhong

机构信息

Department of Otolaryngology, Qianjiang Central Hospital Qianjiang 433100, Hubei, China.

Department of Otolaryngology, Head and Neck Surgery, People's Hospital of Wuhan University Wuhan 430060, Hubei, China.

出版信息

Am J Transl Res. 2024 Jun 15;16(6):2670-2682. doi: 10.62347/GKZE5945. eCollection 2024.

Abstract

PURPOSE

To identify potential clinical diagnostic and prognostic markers for allergic rhinitis (AR) by analyzing a range of inflammatory and clinical markers in a cohort of patients.

METHODS

We conducted a retrospective analysis of clinical data from 493 AR patients treated at Qianjiang Central Hospital from January to March 2023. Patients were categorized based on their outcome. Inclusion and exclusion criteria were strictly applied to select the study population. Various clinical and inflammatory markers were assessed, and statistical analyses were performed to evaluate their diagnostic and prognostic utility.

RESULTS

No significant differences in traditional demographic factors were found between the good and poor prognosis groups (all P > 0.05). However, significant differences were observed in several inflammatory and clinical markers: Interleukin-4 (IL-4) levels were 17.32 ± 4.21 pg/mL in the good prognosis group versus 18.56 ± 5.89 pg/mL in the poor prognosis group (t=2.562, P=0.011). Interleukin-5 (IL-5) levels were 15.65 ± 3.78 pg/mL versus 16.52 ± 4.56 pg/mL, respectively (t=2.221, P=0.027). Transforming growth factor-β1 (TGF-β1) levels were 39.16 ± 8.92 pg/mL versus 41.32 ± 9.67 pg/mL (t=2.513, P=0.012), and histamine levels were 11.87 ± 3.21 ng/mL versus 12.56 ± 4.03 ng/mL (t=1.991, P=0.047). Interleukin-13 (IL-13) levels were 16.32 ± 3.56 pg/mL versus 17.09 ± 4.21 pg/mL (t=2.108, P=0.036). Serum immunoglobulin E (IgE) levels were significantly different, with 164.87 ± 45.32 IU/mL in the good prognosis group compared to 198.56 ± 58.21 IU/mL in the poor prognosis group (t=6.866, P < 0.001). The composite biomarker model demonstrated high predictive value for AR prognosis with an Area Under Curve of 0.906. Individual markers such as TGF-β1, IL-13, and serum IgE levels showed strong diagnostic potential.

CONCLUSION

Our findings underscore the clinical utility of various inflammatory and clinical markers as diagnostic and prognostic indicators for AR. TGF-β1, IL-13, and serum IgE levels, in particular, demonstrated significant diagnostic and prognostic value. An integrated approach combining multiple biomarkers could enhance the accuracy of AR diagnosis and prognosis. Further validation through prospective clinical studies and consideration of treatment interventions are recommended to clarify the clinical implications of these markers.

摘要

目的

通过分析一组患者的一系列炎症和临床标志物,确定变应性鼻炎(AR)潜在的临床诊断和预后标志物。

方法

我们对2023年1月至3月在潜江中心医院接受治疗的493例AR患者的临床资料进行了回顾性分析。根据患者的结局进行分类。严格应用纳入和排除标准以选择研究人群。评估了各种临床和炎症标志物,并进行统计分析以评估其诊断和预后效用。

结果

预后良好组和预后不良组在传统人口统计学因素方面未发现显著差异(所有P>0.05)。然而,在几种炎症和临床标志物方面观察到显著差异:预后良好组白细胞介素-4(IL-4)水平为17.32±4.21 pg/mL,而预后不良组为18.56±5.89 pg/mL(t=2.562,P=0.011)。白细胞介素-5(IL-5)水平分别为15.65±3.78 pg/mL和16.52±4.56 pg/mL(t=2.221,P=0.027)。转化生长因子-β1(TGF-β1)水平为39.16±8.92 pg/mL和41.32±9.67 pg/mL(t=2. 513,P=0.012),组胺水平为11.87±3.21 ng/mL和12.56±4.03 ng/mL(t=1.991,P=0.047)。白细胞介素-13(IL-13)水平为16.32±3.56 pg/mL和17.09±4.21 pg/mL(t=2.108,P=0.036)。血清免疫球蛋白E(IgE)水平有显著差异,预后良好组为164.87±45.32 IU/mL,而预后不良组为198.56±58.21 IU/mL(t=6.866,P<0.001)。复合生物标志物模型对AR预后具有较高的预测价值,曲线下面积为0.906。TGF-β1、IL-13和血清IgE水平等单个标志物显示出较强的诊断潜力。

结论

我们的研究结果强调了各种炎症和临床标志物作为AR诊断和预后指标的临床效用。特别是TGF-β1、IL-13和血清IgE水平显示出显著的诊断和预后价值。结合多种生物标志物的综合方法可提高AR诊断和预后的准确性。建议通过前瞻性临床研究进一步验证并考虑治疗干预措施,以阐明这些标志物的临床意义。

相似文献

5
[Allergic rhinitis management:environment control and patient education].[变应性鼻炎的管理:环境控制与患者教育]
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017 Sep 5;31(17):1315-1321. doi: 10.13201/j.issn.1001-1781.2017.17.005.
7
[Programmed cell death protein 1 and its ligands regulate immune balance in allergic rhinitis].程序性细胞死亡蛋白1及其配体调节变应性鼻炎中的免疫平衡
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2020 Apr 7;55(4):384-390. doi: 10.3760/cma.j.cn115330-20190618-00392.
10
[Expression and significance of Notch1-Jagged1 in allergic rhinitis].Notch1-Jagged1在变应性鼻炎中的表达及意义
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2018 Oct 7;53(10):733-739. doi: 10.3760/cma.j.issn.1673-0860.2018.10.004.

本文引用的文献

3
Aiming to IgE: Drug development in allergic diseases.针对 IgE:变应性疾病中的药物研发。
Int Immunopharmacol. 2023 Aug;121:110495. doi: 10.1016/j.intimp.2023.110495. Epub 2023 Jun 20.
5
Allergic Rhinitis.变应性鼻炎
Prim Care. 2023 Jun;50(2):159-178. doi: 10.1016/j.pop.2023.01.003. Epub 2023 Mar 8.
10
Update on pathomechanisms and treatments in allergic rhinitis.变应性鼻炎的发病机制和治疗进展。
Allergy. 2022 Nov;77(11):3309-3319. doi: 10.1111/all.15454. Epub 2022 Aug 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验